CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $145,313 | +63.8% | 9,746 | +20.3% | 0.01% | +100.0% |
| Q2 2023 | $88,695 | +366.8% | 8,100 | +36.0% | 0.00% | +200.0% |
| Q1 2022 | $19,000 | -5.0% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $20,000 | -9.1% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $22,000 | -15.4% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $26,000 | -3.7% | 5,958 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $27,000 | -20.6% | 5,958 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $34,000 | -5.6% | 5,958 | +21.1% | 0.00% | 0.0% |
| Q3 2020 | $36,000 | +111.8% | 4,918 | 0.0% | 0.00% | +100.0% |
| Q2 2020 | $17,000 | +142.9% | 4,918 | 0.0% | 0.00% | – |
| Q1 2020 | $7,000 | -30.0% | 4,918 | 0.0% | 0.00% | – |
| Q4 2019 | $10,000 | -60.0% | 4,918 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $25,000 | -28.6% | 4,918 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $35,000 | -46.2% | 4,918 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $65,000 | +66.7% | 4,918 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $39,000 | -27.8% | 4,918 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $54,000 | -18.2% | 4,918 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $66,000 | – | 4,918 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |